Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients
نویسندگان
چکیده
منابع مشابه
Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
Approximately 45% of metastatic colorectal cancer (mCRC) patients with wild-type KRAS exon 2 are resistant to cetuximab treatment. We set out to identify additional genetic markers that might predict the response to cetuximab treatment. Fifty-three wild-type KRAS exon 2 mCRC patients were treated with cetuximab/irinotecan-based chemotherapy as a first- or third-line therapy. The mutational stat...
متن کاملWild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
PURPOSE Cetuximab or panitumumab are effective in 10% to 20% unselected metastatic colorectal cancer (CRC) patients. KRAS mutations account for approximately 30% to 40% patients who are not responsive. The serine-threonine kinase BRAF is the principal effector of KRAS. We hypothesized that, in KRAS wild-type patients, BRAF mutations could have a predictive/prognostic value. PATIENTS AND METHODS...
متن کاملKRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis
Background: Mutations in the EGFR signaling pathway play an important role in the development of colorectal cancer (CRC). Mutations in these genes, like KRAS and BRAF, affect the treatment strategies and associated with poor prognosis and relative resistance to anti-EGFR therapies. Our aim was to conduct a systematic and meta-analysis on all studies that have been conducted on the prevalence of...
متن کاملColorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
With a long-term disease-free survival rate of 35% after multimodal treatment of stages II and III colorectal cancer (CRC) and mean overall survival (OS) of approximately 20 months in the metastatic setting, progress in the management of CRC is faster and the prognosis is better than for other gastrointestinal tumors [1]. Over the last 10 years systemic-targeted therapy has led to hope for furt...
متن کاملcommon kras and braf mutations in colorectal cancer patients
background kras and braf gene mutations are considered as key events in carcinogenesis progression of colorectal cancer. given the importance of these gene mutations evaluations, especially in metastatic patients, in terms of determination of therapeutic strategies, we studied the prevalence of kras and braf mutations in tabriz city. materials and methods deoxyribonucleic acid (dna) extracted...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Chinese Journal of Cancer Research
سال: 2011
ISSN: 1000-9604,1993-0631
DOI: 10.1007/s11670-011-0271-4